Web Exclusives

When clinicians and patients rely on different terminology for the term “cure” in cancer treatment, it can lead to patient dissatisfaction and confusion. Read More ›

Next-generation sequencing at initial workup of the patient with advanced non–small-cell lung cancer can shorten time between diagnosis and treatment and may improve survival. Read More ›

Recent study found that the use of sotorasib after anti–PD-L1 therapy in patients with NSCLC increased the chance of severe adverse events and liver toxicity. Read More ›

Patients with non–small-cell lung cancer with a history of prior radiotherapy before immune checkpoint inhibitor treatment are at increased risk for developing severe pneumonitis. Read More ›

Anxiety and depression in patients with advanced lung cancer are associated with poor outcomes when untreated. Radiotherapy, breathlessness, and fatigue are among top predictors of these debilitating conditions. Read More ›

Study evaluates factors that may help determine whether a patient with advanced non–small-cell lung cancer may benefit from the use of immune checkpoint inhibitors. Read More ›

In patients with non–small-cell lung cancer, KRAS G12C mutation is associated with female sex, smoking, and adenocarcinoma and the risk of development of central nervous system metastasis. Read More ›

Analysis reveals factors associated with the development of immune-related adverse events in patients with advanced non–small-cell lung cancer treated with immunotherapy. Read More ›

Recent survey results of physicians who treat patients with non–small-cell lung cancer reveal high biomarker testing rates, but treatment decisions frequently depend on test result turnaround time. Read More ›

Newly diagnosed patients who adhered to tumor board recommendations for treatment have a longer overall survival time than patients who only partially adhered or did not adhere to recommendations. Read More ›

Page 1 of 47


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: